Trial
NCT06752876
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Caribou Biosciences, Inc.
Collaborators
—
Condition
Systemic Lupus Erythematosus
Intervention
CB-010
Why stopped
Sponsor Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-19